Information:
Fel:
ID
18194
Beskrivning
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00193557
Länk
https://clinicaltrials.gov/show/NCT00193557
Nyckelord
Versioner (1)
- 2016-10-24 2016-10-24 -
Uppladdad den
24 oktober 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Multiple Myeloma NCT00193557
Eligibility Multiple Myeloma NCT00193557
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Myeloma NCT00193557
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Criteria Fulfill
Item
to be included in this study, you must meet the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,2])
Multiple Myeloma
Item
multiple myeloma
boolean
C0026764 (UMLS CUI [1])
Prior Therapy Quantity Multiple Myeloma
Item
received no more than 2 previous treatment regimens for multiple myeloma
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])
ECOG performance status
Item
ecog performance status 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine < 2.0mg/dl
boolean
C0201976 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula | Creatinine clearance measurement
Item
calculated or measured creatinine clearance > 30ml/minute
boolean
C2711451 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
C0373595 (UMLS CUI [2])
Measurable Disease | Evaluable Disease
Item
measurable or evaluable disease
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
C1516986 (UMLS CUI [2])
Informed Consent
Item
provide written informed consent prior to receiving protocol therapy.
boolean
C0021430 (UMLS CUI [1])
Study Subject Participation Status
Item
you cannot participate in this study if any of the following apply to you:
boolean
C2348568 (UMLS CUI [1])
Peripheral Neuropathy | CTCAE Grades
Item
moderate or severe peripheral neuropathy
boolean
C0031117 (UMLS CUI [1])
C1516728 (UMLS CUI [2])
C1516728 (UMLS CUI [2])
Other medical condition Serious
Item
other serious medical conditions
boolean
C3843040 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,2])
Malignant Neoplasms
Item
other active malignancies
boolean
C0006826 (UMLS CUI [1])
Therapeutic procedure Invasive cancer
Item
history of treatment for other invasive cancers
boolean
C0087111 (UMLS CUI [1,1])
C0677898 (UMLS CUI [1,2])
C0677898 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
women who are pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Clinical Trial Eligibility Criteria Additional
Item
please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])